VolitionRX (NYSEAMERICAN:VNRX) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS

VolitionRX (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Thursday. The medical research company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.18, Zacks reports. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.71 million.

VolitionRX Stock Up 17.6%

VNRX traded up $0.03 during midday trading on Friday, hitting $0.22. The company had a trading volume of 49,991,046 shares, compared to its average volume of 3,037,621. VolitionRX has a 52 week low of $0.16 and a 52 week high of $7.73. The company has a market capitalization of $2.96 million, a price-to-earnings ratio of -0.06 and a beta of 1.16. The stock’s 50 day moving average price is $0.23 and its 200 day moving average price is $1.95.

Analyst Ratings Changes

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRX in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.00.

VolitionRX Company Profile

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions. The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.